Accepted for/Published in: Interactive Journal of Medical Research
Date Submitted: Oct 20, 2023
Open Peer Review Period: Oct 19, 2023 - Nov 3, 2023
Date Accepted: Jul 30, 2024
Date Submitted to PubMed: Jul 30, 2024
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Emerging Indications for Hyperbaric Oxygen Treatment: A Registry Cohort Study
ABSTRACT
Background:
Hyperbaric oxygen (HBO2) treatment is used across a range of medical specialties for a variety of applications, particularly where hypoxia and inflammation are important factors. HBO2 may be useful for new indications not currently approved by the Undersea and Hyperbaric Medical Society (UHMS) because of its hypoxia-relieving effects. Identifying these new applications for HBO2 is difficult because individual centers may only treat a few cases and not track outcomes in a consistent way. The web-based International Multicenter Registry for Hyperbaric Oxygen Therapy captures outcomes data for patients treated with hyperbaric oxygen (HBO2) therapy. These data can then be used to identify new applications for HBO2.
Objective:
Identify cases where HBO2 is used for indications other than the current UHMS approved indications and present existing outcome data for them.
Methods:
This is a descriptive study based on a web-based, multi-center, international, registry of patients treated with HBO2. Centers agree to collect data on all patients treated using standard outcome measures and send deidentified data from individual centers to the central registry. HBO2 treatment programs in the United States, United Kingdom, and Australia participated. Demographic, outcome, complication, and treatment data, including pre- and post-treatment quality of life questionnaires (EQ-5D-5L) were collected on individuals referred for HBO2 treatment.
Results:
Out of 7545 patient entries, 354 individuals were treated for 44 emerging indications. Post-acute COVID syndrome (PACS) (148), ulcerative colitis (45), and Crohn’s disease (34), accounted for 64% of total cases. Calciphylaxis (18) and peripheral-vascular-disease related wounds (11) accounted for a further 8%. PACS patients reported significant improvement on the Neurobehavioral Symptom Inventory. Crohn’s disease patients reported significantly improved fistula drainage and ulcerative colitis patients reported lower scores on a bowel questionnaire examining frequency, blood, pain, and urgency. A subset of calciphylaxis patients also improved.
Conclusions:
HBO2 is being used for a wide range of possible applications across various medical specialties for its hypoxia-relieving and anti-inflammatory effects. Results show significant improvements in patient reported outcomes for inflammatory bowel disease and PACS. Clinical Trial: DERR1-10.2196/18857
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.